IMNM - Immunome Inc.

QQQ $ 431.55 $ 3.54 (0.83 %)

DIA $ 383.10 $ 2.33 (0.61 %)

SPY $ 509.22 $ 1.03 (0.2 %)

TLT $ 88.26 $ -0.01 (-0.01 %)

GLD $ 216.50 $ -0.78 (-0.36 %)

Previous Close

$ 14.26

Open

$ 14.34

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 13.76 - $ 14.34

52 Week Range

$ 4.44 - $ 30.96

Volume

737,149

Average Volume

Market Cap

282.97M

Beta (5Y Monthly)

$ 1.71

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-28-2024	12-31-2023	10-K
2	11-09-2023	09-30-2023	10-Q
3	08-09-2023	06-30-2023	10-Q
4	05-05-2023	03-31-2023	10-Q
5	03-16-2023	12-31-2022	10-K
6	11-14-2022	09-30-2022	10-Q
7	08-05-2022	06-30-2022	10-Q
8	05-12-2022	03-31-2022	10-Q
9	03-28-2022	12-31-2021	10-K
10	11-15-2021	09-30-2021	10-Q
11	08-16-2021	06-30-2021	10-Q
12	05-12-2021	03-31-2021	10-Q
13	03-25-2021	12-31-2020	10-K
14	11-16-2020	09-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Guggenheim Initiates Coverage On Immunome ...
04/15/2024 10:34:05

Guggenheim analyst Michael Schmidt initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target...

Immunome Files For Shelf Of Up To 2.2M Sha...
04/03/2024 20:51:13

- SEC Filing

Immunome Inc Filed Prospectus Relates To P...
04/03/2024 20:49:31

- SEC Filing

Wedbush Maintains Outperform on Immunome, ...
04/01/2024 11:58:37

Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $27 t...

Immunome Q4 Adj EPS $(0.15) Beats $(0.28) ...
03/29/2024 03:37:37

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 4...

stocks-pause-as-traders-reassess-interest-rate-path-gold-makes-new-highs-bitcoin-rebounds-whats-driving-markets-thursday

Stocks Pause As Traders Reassess Interest ...
03/28/2024 17:49:57

In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting so...

worthington-steel-posts-upbeat-results-joins-summit-midstream-partners-fedex-and-other-big-stocks-moving-higher-on-friday

Worthington Steel Posts Upbeat Results, Jo...
03/22/2024 14:08:47

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.

Immunome Selects Arrayjet's ArrayPlex Plat...
03/18/2024 09:51:29

Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has be...

biotech-stocks-surge-to-start-2024-charts-look-great-but-will-the-trend-continue

Biotech Stocks Surge To Start 2024: 'Chart...
02/28/2024 17:51:20

The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of ...

IMUNON, Inc. Announces IMNN-101 Preclinica...
02/22/2024 13:25:47

Data Show Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccine ModalityLAWRENCEVILLE, N.J., Feb. 2...

Immunome Recognizes Ayala Pharmaceuticals'...
02/20/2024 13:17:43

– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month –

Immunome Prices Public Offering Of 10M Com...
02/14/2024 07:38:12

The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses...

Immunome Announces Proposed $200M Public O...
02/13/2024 21:42:15

Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-c...

12-health-care-stocks-moving-in-tuesdays-intraday-session

12 Health Care Stocks Moving In Tuesday's ...
02/06/2024 17:31:29

Immunome To Acquire AL102 And AL101 Drug C...
02/06/2024 13:06:41

Wedbush Maintains Outperform on Immunome, ...
01/23/2024 13:01:02

Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $12 t...

Immunome, Zentalis Enter Exclusive, Worldw...
01/08/2024 12:15:51

Under the terms of the deal, Zentalis will receive an up-front payment of $35 million in cash and Immunome common stock. Zental...

Immunome To Acquire Antibody-Related Asset...
12/26/2023 13:31:47

Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer th...

Wedbush Initiates Coverage On Immunome wit...
12/19/2023 12:40:48

Wedbush analyst David Nierengarten initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating and announces Price...

Immunome Q3 EPS $(0.36) Up From $(0.75) Yo...
11/09/2023 13:21:48

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.36) per share. This is a 52 percent increase over losses of $(0.75) per...